Clinical and functional benefits of adding theophylline to a standard treatment with short acting bronchodilators in patients with COPD;Beneficios clínicos y funcionales de agregar teofilina a la terapia inhalatoria con broncodilatadores de acción corta en pacientes con enfermedad pulmonar obstructiva crónica

Revista Medica de Chile

Volumn 133, Issue 10, 2005, Pages 1211-1219

  Dreyse D, Jorge ^b   Silva D, Felipe ^b   Díaz P, Orlando ^a   Borzone T , Gisella ^a   Lisboa B, Carmen ^a,b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PUC ^*  (Chile)

Author keywords

Bronchodilator agents; Chronic obstructuve; Pulmonary disease; Theophylline; Xanthines

Indexed keywords

BRONCHODILATING AGENT; IPRATROPIUM BROMIDE; SALBUTAMOL; THEOPHYLLINE;

AGED; ARTICLE; BLOOD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DYSPNEA; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INSPIRATORY CAPACITY; MALE; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSPNEA; FEMALE; HUMANS; INSPIRATORY CAPACITY; IPRATROPIUM; MALE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; THEOPHYLLINE;

EID: 30944449229     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. PAUWELS RA, BUIST AS, CALVERLEY PMA, JENKINS CR. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76.
2. BARNES PJ. Theophylline. New perspectives for an old drug. Am J Respir Crit Care Med 2003; 167: 813-8.
3. MAHLER DA, DONOHUE JF, BARBEE RA, GOLDMAN MD, GROSS NJ, WISNIEWSKI ME ET AL. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-65.
4. ROSSI A, KRISTUFEK P, LEVINE BE, THOMSON MH, TILL D, KOTTAKIS J ET AL. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral slow release theophylline in the treatment of COPD. Chest 2002; 121: 1058-69.
5. ZUWALLACK RL, MAHLER DA, REILLY D, CHURCH N, EMMETT A, RICKARD K ET AL. Salmeterol plus theophylline combination in the treatment of COPD. Chest 2001; 119: 1661-70.
6. O'DONNELL DE, WEBB KA. Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation. Am Rev Respir Dis 1993; 148: 1351-7.
7. DÍAZ O, VILLAFRANCA C, GHEZZO H, BORZONE G, LEIVA A, MILIC-EMILI J ET AL. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J 2000; 16: 269-75.
8. NEWTON MF, O'DONNELL DE, FORKET L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121: 1042-50.
9. DI MARCO F, MILIC-EMILI J, BOVERI B, CARLUCCI P, SANTUS P, CASANOVA F. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003; 21: 86-94.
10. MANRÍQUEZ J, DÍAZ O, BORZONE G, LISBOA C. Reversibilidad espirométrica en la enfermedad pulmonar obstructiva crónica. Efecto diferencial del salbutamol sobre el volumen espiratorio forzado del primer segundo y el volumen pulmonar. Rev Méd Chile 2004; 132: 787-93.
11. MURCIANO D, AUCLAIR MH, PARIENTE R, AUBIER M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320: 1521-5.
12. CHRYSTYN H, MULLEY B, PEAKE M. Dose response relation to oral theophylline in severe chronic obstructive airway disease. BMJ 1988; 297: 1505-10.
13. MCKAY SE, HOWIE CA, THOMSON AH, WHITING B, ADDIS GJ. Value of teophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 1993; 48: 227-32.
14. TAYLOR DR, BUICK B, KINNEY C, LOWRY RC, MCDEVITT DG. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis 1985; 131: 747-51.
15. DULLINGER D, KRONENBERG R, NIEWOEHNER DE. Efficacy of inhaled metaproterenol and orally-administered theophylline in patients with chronic airflow obstruction. Chest 1986; 89: 171-3.
16. TSUKINO M, NISHIMURA K, IKEDA A, HAJIRO T, KOYAMA H, IZUMI T. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998; 53: 269-73.
17. NISHIMURA K, KOYAMA H, IKEDA A, IZUMI T. Is oral theophylline effective in combination with both inhaled anticholinergic agent and inhaled B2 agonist in the treatment of stable COPD? Chest 1993; 104: 179-84.
18. NISHIMURA K, KOYOMA H, IKEDA A, SUGIURA N, KAWAKATSU K, IZUMI T. The additive of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest 1995; 107: 718-23.
19. AMERICAN THORACIC SOCIETY. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-36.
20. SIAFAKAS NM, VERMEIRE P, PRIDE NB, PAOLETTI P, GIBSON J, HOWARD P. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-420.
21. BLACK LF, HYATT RE. Maximal respiratory pressures. Normal values and relationship to age and sex. Am Rev Respir Dis 1969; 99: 696-702.
22. BUTLAND RJA, PANG J, GROSS ER, WOODCOCK AA, GEDDES DM. Two, six and 12 minute walking tests in respiratory diseases. BMJ 1982; 284: 1607-8
23. BORG GAV. Psychophysical basis of perceived exertion. Med Sci Sports Exerc 1982; 4: 377-81.
24. REDELMEIR DA, BAYOUMI AM, GOLDSTEIN RS, GUYATT GH. Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155: 1278-82.
25. MAHLER DA, WELLS C. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93: 580-6.
26. GUELL R, CASAN P, SANGENIS M, SENTIS J, MORANTE F, BORRAS JM ET AL. Traducción española y validación de un cuestionario de calidad de vida en pacientes con enfermedad pulmonar obstructiva crónica. Arch Bronconeum 1995; 31: 202-10.
27. JAESCHKE R, SINGER AL, GUYATT GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-15.
28. MAHLER DA, MATTHAY RA, ZINDER PE, WELLS CK, LOKE J. Sustained release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis 1985; 131: 22-5.
29. VILLANUEVA F, BELLO S, CARRASCO E, SEPÚLVEDA R, VICHERAT L, BARAHONA R ET AL. Caracterización de los pacientes portadores de enfermedad pulmonar obstructiva crónica y su respuesta a ipratropio y a teofilina. Rev Chil Enf Respir 1999; 15: 163-71.
30. AUBIER M, DE TROYER A, SAMPSON M, MACKLEM PT, ROUSSOS CH. Amynophylline improves diaphragmatic contractility. N Eng J Med 1981; 305: 249-52.
31. MOXHAM J. Amynophylline and the respiratory muscles: An alternative view. Clin Chest Med 1988; 9: 325-40.
32. RAM FSF, JARDIN JR, ATALLAH A, CASTRO AA, MAZZINI R, GOLDSTEIN R ET AL. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Evidence-based review. Respir Med 2005; 99:135-44.
33. BELLIA V, FORESI A, BIANCO S, GRASSI V, OLIVIERI D, BENSI G ET AL. Efficacy and safety of oxitropium bromide, theophylline and their combination in COPD patients: a double-blind ramdomized, multicentre study (BREATH TRIAL). Respir Med 2002; 96: 881-9.
34. OHTA K, FUKUCHI Y, GROUSE L, MIZUTANI R, RABE KF, RENNARD S ET AL. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir Med 2004; 98: 1016-24.
35. CELLI BR, MACNEE W, AGUSTI A, ANZUETO A, BERG B, BUIST AS ET AL. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-46.
36. Chronic Obstructive Pulmonary Disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59 (Suppl 1): i39-i130.